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The clinical diagnosis of a patient with the phenotype of Ehlers–Danlos syndrome type VI was conﬁrmed bio-
chemically by the severely diminished level of lysyl hydroxylase (LH) activity in the patient’s skin ﬁbroblasts. A
novel homozygous mutation, a single base change of T1360 ! G in exon 13 of the LH1 gene, predicted to result in
W446G, was identiﬁed in the patient’s full-length cDNA. This was conﬁrmed in genomic DNA from both the patient
and her parents, who were heterozygous for the mutation. This mutation was introduced into an LH1-pAcGP67
baculoviral construct and expressed, in parallel with normal LH1, in an insect cell system. The loss of LH activity in
the mutated recombinant construct conﬁrmed the pathogenicity of this mutation. Although not in the major cat-
alytic site, this mutation occurs in a highly conserved region of the LH1 gene and may contribute to loss of activity
by interfering with normal folding of the enzyme.
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Patients with the rare autosomal recessive disorder Ehlers–
Danlos syndrome type VIA (EDS VIA; online Mendelian in-
heritance in man (OMIM) no. 225400), the kyphoscoliosis
type of EDS (Beighton et al, 1998), have the clinical phe-
notype of hypermobile joints, soft hyperextensible skin that
is prone to bad scarring and easy bruising, and kyphosco-
liosis (Byers, 2001; Steinmann et al, 2002). The biochemical
basis for this disorder is because of severely decreased
levels of lysyl hydroxylase (LH) (Pinnell et al, 1972), an en-
zyme that hydroxylates specific lysines in collagen (Kivirikko
and Pihlajaniemi, 1998). The hydroxylysines are precursors
for the formation of cross-links that are essential for the
tensile strength of collagen. A second, rarer form of EDS VI
has been described, EDS VIB (OMIM no. 229200), in which
patients have the clinical phenotype of EDS VI but with
normal levels of LH activity (Walker et al, 2004a).
In this study of a patient with the characteristic clinical
phenotype of EDS VIA and severely diminished levels of LH
activity, we have identified a novel homozygous mutation
T1360 ! G in exon 13 of the LH1 gene predicted to result in
an amino acid change W446G. Using structure–function
analysis in a baculoviral system, we have confirmed that
this mutation causes the decreased LH activity associated
with the clinical phenotype of EDS VIA.
Patient Summary
The patient, a 5-y-old girl of Turkish origin, is the daughter of
consanguineous parents. She was born at term after a nor-
mal pregnancy. At birth, she presented generalized joint
laxity without obvious muscle hypotonia, and a mild
scoliosis. The neuromotor development was normal in the
first year of life, and the child started to walk independently
at 14 mo. She then developed a progressive kyphoscoliosis
causing chronic back pain. She has no history of joint dis-
locations or fractures. The wound healing is delayed with
formation of atrophic scars. She bruises easily upon mild
trauma. There is no history of internal bleeding.
Clinical examination at the age of 5 y revealed general-
ized joint laxity, severe kyphoscoliosis, and mild pectus ex-
cavatum (Fig 1A and B). Her skin was hyperextensible and
she presented multiple atrophic scars on the legs, the hips,
and the shoulders. She did not present a marfanoid habitus.
Scleral hue was normal. Ultrasonography of the heart did
not reveal any abnormalities. Ophthalmologic examination
was not performed. The clinical investigation was conduct-
ed according to the Declaration of Helsinki principles.
Abbreviations: DHLNL, dihydroxylysinonorleucine; EDS VIA, Eh-
lers–Danlos syndrome type VIA; HLNL, hydroxylysinonorleucine;
LH1, lysyl hydroxylase 1; OMIM, online Mendelian inheritance in
man; PH, prolyl 4-hydroxylase
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Results
EDS VIA patient has severely decreased LH activity LH
activity was measured in the cell extracts of skin fibroblasts
cultured from the patient (1270) and a control (842), in a
tritium release assay that measures predominantly helical
LH activity (Walker et al, 2004b). The level of activity in the
EDS VIA patient was significantly decreased to 17%  3%
of control. The LH/prolyl 4-hydroxylase (PH) ratio was sim-
ilarly decreased (Dembure et al, 1984).
Bi-functional collagen cross-linking is decreased in EDS
VIA patient We then examined bi-functional collagen
cross-linking in cell matrices from long-term cultures of fib-
roblasts from patient 1270 and three other patients char-
acterized as EDS VIA, compared with a control. Two major
reducible cross-links were identified from the analyses, i.e.
dehydro-dihydroxylysinonorleucine (deH-DHLNL) and de-
hydro-hydroxylysinonorleucine (deH-HLNL). Those cross-
links were measured as their reduced forms, DHLNL and
HLNL, respectively. Other cross-links such as pyridino-
line, deoxypyridinoline, and histidinohydroxylysinonorleucine
were below the detectable range. As shown in Table I, the
levels of the monohydroxylated cross-link HLNL did not
show much variability between patients and control, where-
as in patient 1270 and the three other EDS VIA patients, the
levels of the dihydroxylated cross-link DHLNL and the cor-
responding ratios of DHLNL/HLNL were decreased to less
than 20% of control.
Identiﬁcation of mutation in cDNA from patient 1270;
conﬁrmation of homozygosity in genomic DNA The full-
length 2.2 kb cDNA for LH1 was amplified as a single tran-
script and directly sequenced from dermal fibroblasts from
patient 1270 to identify the mutation(s) in the LH1 gene that
would cause the decreased LH activity. The direct se-
quence analysis of the cDNA identified a single point mu-
tation T1360 ! G in exon 13 of the LH1 gene (TGG ! GGG),
which would be predicted to result in the change of a try-
ptophan at residue 446 to a glycine (W446G). The mutation
was confirmed by PCR amplification of genomic DNA from
both the patient and her parents. Direct sequencing of the
600 bp fragment covering the mutation showed that the
mutation had been correctly identified and that this patient
was homozygous for the mutation. The heterozygosity of
both parents for this mutation confirmed the homozygosity
of the mutation in their daughter.
Structure/function analysis of W446 mutation As the
mutation identified in the LH1 gene from the patient, al-
though novel, would not be predicted to either terminate or
disrupt the reading frame of the LH1 gene, we utilized our
baculovirus system to express the mutated LH1 and con-
firm that the T1360 ! G mutation is responsible for the loss
of LH activity. The T1360 ! G mutation was introduced into
the normal LH1-pAcGP67 baculoviral construct by site-di-
rected mutagenesis, followed by cotransfection, amplifica-
tion of the viral stocks, and expression in Sf9 insect cells.
The non-mutated LH1cDNA baculoviral construct was am-
plified and expressed in parallel.
Assay of LH activity on the secreted normal and mutant
proteins showed, in comparison with the high activity of
normal LH1 (11.3  103 cpm per mg total protein), a com-
plete loss of activity in the mutated protein. This confirmed
that the predicted W446G change was responsible for the
severely decreased LH activity measured in skin fibroblasts
from the patient.
We used RT-PCR to examine whether degradation of
LH1 mRNA in the mutant construct could be the reason for
the loss of enzyme activity. In cells infected with normal and
mutant LH1, however, levels of LH1 mRNA were shown to
be equally expressed, indicating that mRNA degradation
had not occurred (Fig 2).
Figure 1
Patient 1270. (A) Patient 1270 at the age of 4 y. Note the severe
kyphoscoliosis and pectus excavatum. Her skin is soft and hyperex-
tensible. (B) Severe scoliosis at the age of 4 y.
Table I. Reducible bi-functional collagen cross-links in cells
from EDS VIA patients compared with control (CON)
EDS VIA
CON 1270 1122 1268 1272
DHLNL 0.52 0.09 0.1 0.08 0.07
HLNL 0.31 0.49 0.5 0.39 0.27
DHLNL/HLNL 1.7 0.19 0.2 0.2 0.27
Cross-links were measured in long-term cultures of cells as described
in Materials and Methods. Reducible cross-links (moles/mole collagen)
were measured as their reduced forms as shown.
DHLNL, dihydroxylysinonorleucine; HLNL, hydroxylysinonorleucine,
expressed as a ratio of DHLNL/HLNL; EDS VIA, Ehlers–Danlos syn-
drome type VIA.
Figure2
RT-PCR of mRNA isolated from insect cells 24 h post-infection
with baculoviral stocks of recombinant normal and mutated lysyl
hydroxylase 1 (LH1) RNA was isolated from insect cells and cDNA
template prepared as described. One hundred fourteen base pair
PCR fragments were amplified from cells infected with mutant LH1
(lane 3), cells infected with normal LH1 (lane 4), but not from cells alone
(lane 2). Lane 1 represents the blank for the PCR reaction. LH1 mRNA
appears to be equally expressed from normal and mutated LH1-ba-
culoviral cell extracts.
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W446G mutation is located in a highly conserved region
of the LH1 gene Using NCBI’s resource tools Homologene,
UniGene, and BLAST (http://www.ncbi.nlm.nih.gov) and
Phylo-HMM, and Multiz from the UCSC Genome Browser
(http://genome.ucsc.edu), we compared the LH1 sequenc-
es in the region of the mutation between the human LH
isoforms and across multiple species. As shown in Fig 3,
both the tryptophan and the surrounding residues are highly
conserved, suggesting that this region is important for the
activity of the enzyme.
Discussion
The clinical diagnosis of EDS VIA is confirmed at the bio-
chemical level by a deficiency of the important collagen-
modifying enzyme, LH. This enzyme deficiency results from
different mutations in the LH1 gene, many of which code for
premature termination codons or disrupt the reading frame
of LH1 (Yeowell and Walker, 2000). In this study, we have
identified a novel homozygous point mutation in exon 13 of
the LH1 gene that changes a codon for tryptophan to a
codon for glycine at amino acid residue 446 (W446G) in a
patient with EDS VIA. Although this mutation does not ter-
minate or cause a frameshift in the LH1 gene, we have
shown by structure–function analysis that it is responsible
for the severely diminished levels of LH activity in this
patient.
The diminished LH activity in EDS VIA patients leads to
decreased hydroxylysine content in collagen. Hydroxylysine
residues have two important functions. They are essential
for the stability of the intermolecular collagen cross-links
that provide collagen with its tensile strength, and their hy-
droxyl groups can serve as sites for the addition of carbo-
hydrate units, either the monosaccharide galactose or the
disaccharide glucosylgalactose (Kivirikko and Pihlajaniemi,
1998). The underglycosylation that results from the de-
creased hydroxylysine content of collagen in EDS VIA pa-
tients causes increased electrophoretic mobility of the a
chains of type I collagen. We have observed this increased
mobility of collagen chains in the current patient (data not
shown), which is a consequence of the loss of LH activity
and supports the diagnosis of EDS VIA. The location of the
hydroxylysines within the collagen molecule, either in the
telopeptide or helical domains, plays an important role in
the formation of specific intermolecular collagen cross-links
that determine the strength of the collagen matrix. In skin
fibroblasts, the two measurable major cross-links, DHLNL
and HLNL (as their reduced forms), are formed by conden-
sation reactions between telopeptidyl hydroxylysine-alde-
hyde and helical hydroxylysine and between telopeptidyl
lysine-aldehyde and helical hydroxylysine, respectively. A
combination of telopeptidyl hydroxylysine-aldehyde and
helical lysine is also possible, but in soft connective tissues
the former is predominant. Therefore, if the level of the
DHLNL or ratio of the DHLNL/HLNL cross-links is reduced,
this may imply a decrease in telopeptide lysine hydroxylat-
ion. We observed significantly decreased DHLNL levels in
long-term cultures of fibroblasts both from the patient and
three additional patients with confirmed EDS VIA. Although
LH1 is considered to act as a helical lysine hydroxylase,
these cross-linking results indicate that this isoform also has
telopeptide LH activity. This telopeptide-based activity has
been demonstrated in studies showing increased levels of
the tri-functional cross-link, pyridinoline, in cells expressing
recombinant rat LH1 (Mercer et al, 2003). As this cross-link
is formed via the telopeptidyl hydroxylysine-aldehyde path-
way, this provides further evidence for the telopeptide LH
activity of LH1.
The T1360 ! G mutation that we have characterized in
LH1 in the EDS VIA patient is a novel point mutation in exon
13 of the gene predicted to code for W446G. As this
mutation lacks the obviously disruptive features of, for
example, introducing a premature termination codon
or interfering with the reading frame of the LH1 gene, we
proved that this mutation was causal for the decreased LH
activity by structure–function analysis using an LH1cDNA-
pAcGP67 baculoviral construct. We have previously used
this system to individually mutate the ten cysteines in the
LH1 gene and determine their relative contribution to LH
activity (Yeowell et al, 2000a). In this study, we introduced
the mutation into the normal LH1 baculoviral construct by
site-directed mutagenesis, amplified viral stocks, and ex-
pressed both normal and mutated recombinant proteins in
their potentially secretable forms. The lack of activity in the
mutant LH1 secreted fraction as compared with the high
activity of non-mutated LH1 indicated that W446 was re-
quired for LH activity. Moreover, this result strongly sug-
gested that this mutation is causal for the clinical phenotype
of EDS VIA in patient 1270.
During the course of our analysis of mutations in the LH1
gene in EDS VIA patients, we have often observed a lack of
detectable mRNA for LH1 in northern analysis of RNA iso-
lated from the patients’s fibroblasts. This has been generally
attributed to the presence of nonsense or frameshift muta-
tions in the LH1 gene that make the mRNA subject to rapid
mRNA degradation (Maquat, 1995). To examine whether the
point mutation we had identified in the LH1 gene made it
vulnerable to accelerated mRNA degradation, we isolated
mRNA from cells in which the mutant recombinant LH1 had
been expressed, together with cells expressing normal LH1.
Human LH1 AA # 444 445 446 447 448 449 450
Human LH1 (Homo sapiens) G V N V P Y 
Human LH2 G V W N V P Y 
Human LH3 G V W N V P Y 
Chimp (Pan troglodyte) G V W N V P Y 
Pig (Sus scrofa) G V W N V P Y 
Cow (Bos taurus) G V W N V P Y 
Mouse LH1 (Mus musculus) G V W N V P Y 
Mouse LH2 G I W N V P Y 
Mouse LH3 G V W N V P Y 
Rat LH1 (Rattus norvegicus) G V W N V P Y 
Rat LH2 G I W N V P Y 
Rat LH3 G L W N V P Y 
Chicken LH1 (Gallus gallus) G P W N V P Y 
Chicken LH2  G V W N I P Y 
Frog (Xenopus laevis) G V W N V P Y 
Zebra fish (Tetradon nigroviridis) G V W N V P Y 
Malaria mosquito (Anopheles gambiae) G L W N V P Y 
Caenorhabditis elegans G Y W N V P F 
Drosophila melanogaster G M F N V P H 
W 
Figure 3
Alignment of the sequence region of human lysyl hydroxylase 1
(LH1) in which mutation is located with the sequence of the dif-
ferent human LH isoforms and the LH isoforms of different spe-
cies. The location of mutation of tryptophan (W) (black box) in human
LH1 is shown to be in a region of high homology (gray boxes) compared
with different human LH isoforms and LH isoforms of different species.
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Using RT-PCR, we showed equivalent amplification of LH1
from both the mutant and normal LH1 mRNA, indicating that
this mutation permits accumulation of stable mRNA and
that degradation of mRNA is not a contributing factor to the
loss of activity and decreased expression of the mutant
protein.
The mutations in LH1 that are causal for the clinical phe-
notype of EDS VIA are shown to be located throughout the
LH1 gene (Yeowell and Walker, 2000). In the majority of
the more than 20 different mutations identified, both ho-
mozygous and heterozygous, there is an obvious reason for
why they cause such a dramatic decrease in LH activity.
These include the nonsense mutations, the splice site mu-
tations causing out-of-frame exon deletions, and the inser-
tions and deletions that disrupt the reading frame of LH1.
The W446G mutation that we have identified in this study
does not have such an obvious effect. One explanation for
its effect on LH activity could be because of the difference
in the size of the affected amino acids. Replacement of the
bulky tryptophan moiety by glycine, the smallest amino
acid, could produce a significant conformational change
and possibly interfere with protein folding, subsequently
causing a loss of catalytic activity. We have also shown that
this mutation, although not located in the highly conserved
terminal region of the LH1 gene containing the catalytic site,
is located in a different highly conserved region in which the
tryptophan residue, with one exception, is invariant in the
human LH isoforms and between species. This suggests
that it may be important to evaluate this domain in future
functional studies of this enzyme.
Materials and Methods
Cell culture Human dermal fibroblasts from the proband (1270),
other previously described EDS VIA patients (1122, 1268, and
1272) (Yeowell et al, 2000b), and from a normal control (842)
(GM05659, Coriell Institute for Medical Research, Camden, New
Jersey) were cultured as described (Murad et al, 1985). Informed
consent was obtained for use of these cell lines.
LH assay LH activity in extracts from fibroblasts and recombinant
enzyme expressions was measured with an L-[4,5-3H] lysine-labe-
led underhydroxylated procollagen substrate as described (Murad
et al, 1985; Krol et al, 1996). PH activity was measured with a
similar underhydroxylated procollagen substrate labeled with L-
[4-3H] proline. The enzyme activities were quantitated as released
3H2O in a minimum of four assays.
Electrophoretic analysis of (pro)collagen molecules Pepsin-
digested procollagen isolated from patient fibroblasts labeled with
14C-proline were analyzed by SDS-PAGE as described (Nuytinck
et al, 1996).
Analysis of cross-linking in long-term ﬁbroblast cultures Re-
ducible bi-functional collagen cross-links were measured in long-
term cultures of patients’s fibroblast cell lines as previously de-
scribed (Walker et al, 2004a).
PCR ampliﬁcation and sequence analysis of DNA from patient
1270 The numbering of the primer pairs is based on LH1cDNA
sequence from dermal fibroblasts (GenBank accession number
M98252). All PCR reactions were performed in a Perkin-Elmer PCR
Thermocycler 480 (Boston, Massachusetts). The products were
sequenced at the Duke DNA sequencing facility.
Full-length LH1cDNA cDNA was prepared in a 20 mL reaction with
1 mg total RNA in ddH2O, isolated as described (Chomczynski and
Sacchi, 1987), 1  iScript reaction mix, and 1 mL iScript Reverse
Transcriptase (Bio-Rad, Hercules, California). The reaction was
then incubated at 251C (5 min); 421C (30 min); and 851C (5 min).
This template cDNA was used to amplify full-length cDNA for LH1
using, as 50 primer GAT ACC TCG GCC ATG CGG CCC CT (be-
ginning at nt 13), and, as 30 primer CCA ATT AGG GAT CGA CGA
CGA AGG AGA CT (beginning at nt 2212), in a 50 mL reaction
containing 0.5 mL of the prepared cDNA, 150 ng of each primer,
0.8 mM dNTP mix, 1  PfuUltra HF Reaction Buffer, and 2.5 U
PfuUltra Hotstart High-Fidelity DNA Polymerase (Stratagene, La
Jolla, California). The reaction was initially denatured at 951C (2
min) followed by three cycles of denaturation at 951C (30 s), an-
nealing at 731C (30 s), and extension at 721C (3 min). The annealing
temperature was then decreased by 31C for three cycles and
maintained at 681C (30 s) for the final 30 cycles, followed by a final
extension of 721C (10 min). Electrophoresis of the PCR products on
a 1% agarose gel showed a single 2.2 kb fragment of full-length
LH1cDNA. The gel-purified cDNAs were directly sequenced.
Conﬁrmation of mutation in genomic DNA Genomic DNA was iso-
lated from the patient’s cultured skin fibroblasts using the Blood &
Cell Culture DNA mini kit (Qiagen, Valencia, California). A 600 bp
fragment covering the mutation was amplified by PCR between
exon 12 and exon 13 using a primer pair of GTC ATT GCC CCG
CTG ATG AC (50 primer, beginning at nt 1231) and GCA CAG AAG
GCC ATG TCG (30 primer, beginning at nt 1488) in a 50 mL reaction
of 2 mg of gDNA, 300 ng of each primer, and 1  Herculase Hot-
start PCR master mix (Stratagene). Touchdown PCR was per-
formed as described for the cDNA amplification, beginning with an
annealing temperature of 611C (30 s) and extension at 721C (1 min),
and was maintained at 571C (30 s) for 30 cycles with addition of
10 s per cycle to 721C extension. Genomic DNA from the parents
was similarly amplified. Electrophoresis of the PCR products on a
3% agarose gel showed predominant 600 bp PCR fragments that
were gel-purified and directly sequenced.
Site-directed mutagenesis The mutation T1360 ! G was intro-
duced into the previously described LH1-pAcGP67 baculoviral
construct (designed for the expression of LH1 in a secretable form)
(Krol et al, 1996), so that a codon for tryptophan (TGG) was
changed to a codon for glycine (GGG), using the QuikChange II
Site-Directed Mutagenesis kit (Stratagene). The 11.7 kb double-
stranded LH1-baculoviral DNA construct was amplified by PCR
using two complementary oligonucleotide primers that introduced
the desired mutation (underlined in bold as shown): 50 primer GG
CGT GTT GGT GTC GGG AAT GTG CCC TAT ATT (beginning at nt
1346) and as 30 primer AAT ATA GGG CAC ATT CCC GAC ACC
AAC ACG CC (beginning at nt 1377). Following clonal selection
according to the manufacturer’s protocol and DNA isolation with
Qiagen’s Plasmid Purification Maxi kit, the mutated LH1 constructs
were sequenced to confirm successful mutagenesis and that the
reading frame was correct.
Expression and analysis of mutated and normal LH1 con-
structs in a baculoviral system Using Sf9 insect cells in HyQ
SFX-insect serum-free medium (HyClone, Logan, Utah), cotrans-
fection, viral amplification, expression of the mutated construct in
parallel with a normal construct, and assay of LH activity were
carried out as described (Yeowell et al, 2000a).
To measure the levels of LH1 mRNA in the recombinant cellular
extracts, RNA was isolated from the Sf9 insect cells 24 h post-
infection with the baculoviral stocks for recombinant normal and
mutant LH1, the wild-type virus, and from untreated cells, using the
Qiagen RNeasy mini kit according to the manufacturer’s protocol.
cDNA was prepared as described and used to amplify a 114 bp
PCR fragment for LH1 using as 50 primer CAA GCG CTC AGC TCA
GTT CTT C (beginning at nt 156) and as 30 primer CTT CAG CAG
CCG GAC CTT CT (beginning at nt 270), in a 50 mL reaction con-
taining 1 mL of the prepared cDNA, 200 ng of each primer, 1.6 mM
NOVEL MUTATION IN LH1 GENE CAUSES EDS VIA 917124 : 5 MAY 2005
dNTP mix, 3.5 mM MgCl2, 1  PCR Buffer II, and 2.5 U Amplitaq
Gold DNA Polymerase (Applied Biosystems, Foster City, Califor-
nia). Touchdown PCR was performed with initial denaturation at
951C (10 min), an annealing temperature of 611C (40 s), and ex-
tension at 721C (30 s); the annealing temperature was decreased
by 21C every two cycles for three times and was maintained at
551C (40 s), for 30 cycles. The PCR products were separated on a
3% agarose gel with ethidium bromide and visualized under UV
light.
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